Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Users Online: 555
About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Advertise Login 
Year : 2012  |  Volume : 1  |  Issue : 4  |  Page : 171-175

Is sildenafil an effective therapy in the management of persistent pulmonary hypertension?

1 Department of Pediatric, University Hospital Sharjah, Sharjah, United Arab Emirates
2 Department of Pediatric, AL Falah Military Hospital, Sharjah, United Arab Emirates

Correspondence Address:
Hakam Yaseen
Department of Pediatric, PO Box 25624, Sharjah
United Arab Emirates
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2249-4847.105958

Rights and Permissions

Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening neonatal pathology resulting from poor hemodynamic and respiratory transition to extra uterine life. Inhaled nitric oxide (iNO) is a current, commonly used treatment of PPHN. However, iNO is not available therapy in many developing countries and around 50% of infants with PPHN do not respond to iNO therapy. Sildenafil is a phosphodiesterase inhibitor type 5 (PDE5) that has been shown to selectively reduce pulmonary vascular resistance in both animal models and adult humans. Recent studies have found that in PPHN, administration of Sildenafil was associated with a significant increase in the oxygenation and a reduction in mortality with no clinically important side effects.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
  Search Pubmed for
  Search in Google Scholar for
Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded6236    
    Comments [Add]    
    Cited by others 9    

Recommend this journal